SEC Form 4 · accession 0001992908-26-000013
NovaBridge Biosciences · NBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert A. Lenz
Director
Period of report
Aug 22, 2026
Accepted (ET)
Aug 25, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001778016
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2,F3 | Aug 22, 2026 | M | 17,218 | — | A | 17,218 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF4,F3,F5 | — | Aug 22, 2026 | M | 7,486 | D | — | — | Ordinary Shares | 7,486 | 14,974 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
- F2Reported securities are represented by 7,486 ADSs.
- F3Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
- F4Reported securities represent ADSs.
- F5On August 22, 2025, the Reporting Person was granted 22,460 restricted share units ("RSUs"). The RSUs vested or shall vest over three years in three equal annual installments on August 22, 2026, 2027 and 2028.